Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma

Curr Drug Targets. 2023 Dec 28. doi: 10.2174/0113894501286195231220094646. Online ahead of print.ABSTRACTGlaucoma is the most common cause of irreversible blindness worldwide. It is characterized by progressive optic nerve degeneration and loss of visual field. Pathological increased intraocular pressure is its main modifiable risk factor. Rho kinase inhibitors are developed as a new class of glaucoma medication that increases outflow facility from the conventional aqueous humor outflow pathway. Additionally, they also have neuropective and anti-scarring effects that can might increase the success rate of glaucoma filtration surgery. This review aims to summarize the current concept of Rho kinase inhibitor in the treatment of glaucoma from beach to bedside.PMID:38155465 | DOI:10.2174/0113894501286195231220094646
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research